481 Results (Page 1 of 20)
UK Markets Research Reports
UK Bariatric Surgery Devices Market Analysis
The UK Bariatric Surgery Devices Market was valued at $212.8 Mn in 2023 and is projected to grow at a CAGR of 5.2% from 2023 to 2023, to $303.4 Mn by 2030. Major factors driving the market for bariatric surgical devices include the rising incidence of adult obesity brought on by altered lifestyle patterns and excessive calorie consumption. The demand for bariatric operations is also anticipated to rise over the forecast period due to increased government backing and growing public awareness of the market's unhealthy food and beverage offerings and how they affect BMI, thus driving the market growth of the Bariatric Surgery Devices. The prominent players in the market are Apollo Endosurgery, Medtronic, B. Braun, Johnson & Johnson, Aspire Bariatrics among others.
UK Patient Engagement Solutions Market Analysis
The UK patient engagement solutions market is projected to grow from $442.26 Mn in 2022 to $961.9 Mn by 2030, registering a CAGR of 10.2% during the forecast period of 2022 - 2030. The main factors driving the growth would be a focus on patient-centred care, the rising prevalence of chronic diseases, rapid growth in digital health firms and government support and initiatives. The market is segmented by component, delivery mode, application, therapeutic area, functionality and by end-user. Some of the major players include Medesk, Cambio Healthcare System, ClinicYou, Orion Health and Open Health.
UK Acne Drugs Market Analysis
This report presents a strategic analysis of the UK Acne Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Acne Drugs Market, offering unmatched value, accuracy and expert insights.
UK Dental Fluoride Treatment Market Analysis
The UK Dental Fluoride Treatment Market was valued at $394.4 Mn in 2023 and is projected to grow at a CAGR of 1.9% from 2023 to 2023, to $449.9 Mn by 2030. The key drivers of this industry are growing prevalence of dental caries coupled with increasing awareness regarding oral health and hygiene, increasing the intake of sugary drinks and food, projected to drive the market. Furthermore, increasing support from the government to improve access to person-cantered treatment and to advance a holistic method of oral health equity has contributed to market growth. The industry is primarily dominated by players such as Waken, Dentocare, Colgate, 3M and Unilever among others.
UK Contact Lenses Market Analysis
UK Contact Lenses Market was valued at $445.64 Mn in 2023 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $710.93 Mn by 2030. The key drivers of this industry include the high prevalence of myopia, growing preference for daily disposables, technological advancements, and rising disposable income. The industry is primarily dominated by Bausch and Lomb, CooperVision, Alcon Vision, and Essilor among others.
UK Retail Pharmacy Market Analysis
UK Retail Pharmacy Market is projected to grow from $27 Bn in 2022 to $39.59 Bn by 2030, registering a CAGR of 4.9% during the forecast period of 2022-30. The development of novel medications for complex conditions in fields including cancer, respiratory, and infectious diseases, supported by NICE appraisals and guidelines, has been the primary driver of growth in the UK retail pharmacy market. Some key players in the UK retail pharmacy market include Boots UK, Lloyds Pharmacy, Well Pharmacy, Superdrug, and Rowlands Pharmacy.
UK Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis
UK Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.
UK Medical Digital Imaging System Market Analysis
The UK Medical Digital Imaging System Market was valued at $793 Mn in 2023 and is predicted to grow at a CAGR of 6.2% from 2023 to 2030, to $1208.22 Mn by 2030. The key drivers of this industry include increasing chronic conditions, government support, and the aging population. The industry is primarily dominated by players such as Siemens Healthineers, GE Healthcare, Philips Healthcare, and Canon Medical Systems among others.
UK Primary Hyperoxaluria (PH) Therapeutics Market Analysis
UK Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
UK Dental Caries Detectors Market Analysis
The UK Dental Caries Detectors Market was valued at $5.9 Mn in 2023 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $9.5 Mn by 2030. UK Dental Caries Detectors Market is growing due to Increasing Dental Awareness and Education, Government Initiatives and Funding, and Technological Advancements. The market is primarily dominated by players such as Dentsply Sirona, KaVo Kerr, Ivoclar Vivadent, Planmeca Oy, Adec Technologies, 3M ESPE, Morita Corporation, Woodpecker Medical Instruments Co., Softdent.
UK Clinical Nutrition for Diabetes Care Market Analysis
The UK Clinical Nutrition for Diabetes Care Market was valued at $55.90 Mn in 2023 and is predicted to grow at a CAGR of 2.78% from 2023 to 2030, to $67.73 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Abbott Nutrition, Nualtra, Clinova Ltd, and Novo Nordisk among others.
UK Pharmacy Automation Device Market Analysis
The UK Pharmacy Automation Device Market was valued at $143 Mn in 2023 and is predicted to grow at a CAGR of 7.9% from 2023 to 2030, to $243.5 Mn by 2030. UK Pharmacy Automation Device Market is growing due to Reducing Human Errors, Adoption of Electronic Health Records, and Increased Demand for Pharmaceuticals. The market is primarily dominated by players such as Chemist Outsource, Paragon Group, Meda UK , KUKA AG, Parata Systems LLC, Dickinson, and Company, Talyst Systems.
UK Cardiac Pacemakers Market Analysis
The UK Cardiac Pacemakers Market was valued at $105.22 Mn in 2023 and is predicted to grow at a CAGR of 1.2% from 2023 to 2030, to $114.38 Mn by 2030. The key drivers of this industry include increasing aging population, advancements in technology, and supportive government initiatives. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
UK Clinical Nutrition Market Analysis
The UK Clinical Nutrition Market was valued at $797.4 Mn in 2023 and is projected to grow at a CAGR of 3.34% from 2023 to 2023, to $1003.6 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as Baxter International Inc., Otsuka Holdings Co., Ltd, Mead Johnson & Company, LLC among others
UK Chronic Myelogenous Leukemia Therapeutics Market Analysis
UK Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.
UK Charcot-Marie-Tooth Disease (CMT) Therapeutics Market Analysis
UK Charcot-Marie-Tooth Disease (CMT) Therapeutics market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. The majority of hereditary peripheral neuropathies are Charcot-Marie-Tooth (CMT) illness, commonly referred to as hereditary motor and sensory neuropathy (HMSN). Genes that support or generate proteins important in the construction and operation of the myelin sheath or the peripheral nerve axon are mutated, leading to CMT. An increase in genetic illnesses will result in more innovations being made in this area, which will enhance market growth because there are many genes that cause these problems. The above-mentioned forecast period will witness the emergence of the market for Charcot Marie-Tooth disease due to multiple prospects that will be heightened by the rising focus on targeted therapies and the favorable government regulations. Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp., Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. are some of the major players in the Charcot Marie Tooth Disease Market.
UK Batten's Disease (CLN-2) Therapeutics Market Analysis
UK Batten?s Disease (CLN-2) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neuronal Ceroid Lipofuscinosis (NCL), often known as Batten disease, is a rare and severe autosomal recessive neurodegenerative lysosomal storage condition brought on by cellular buildup of aberrant auto-fluorescent lipoproteins (lipofuscin). Seizures and a progressive loss of movement, verbal, visual, and cognitive abilities are features of this neurodegenerative condition that primarily affects the nerve system. Research advancements in nanotechnology could result in the creation of fresh therapies that would benefit persons who suffer from this ailment. Additionally, it is a paediatric brain condition that is extremely rare yet progresses quickly. As a result, Batten's Disease may be exacerbated by the predicted rising prevalence of disease. Therapeutics market (CLN-2). The market for Batten's Disease (CLN-2) Therapeutics is constrained by a lack of treatment and symptoms that are challenging to identify. Regenxbio, Polaryx Therapeutics and Abeona Therapeutics are some of the key players in the market.
UK ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis
UK ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.
UK Clinical Nutrition for Cancer Care Market Analysis
The UK Clinical Nutrition for Cancer Care Market was valued at $146.4 Mn in 2023 and is predicted to grow at a CAGR of 3.04% from 2023 to 2030, to $180.5 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the UK Clinical Nutrition for Cancer Care Market are Baxter, Nestlé Health Science, Abbott Nutrition, Nutricia, and Fresenius Kabi, among others.
UK Gram-Negative Infection Therapeutics Market Analysis
The UK Gram-Negative Infection Therapeutics Market was valued at $386.8 Mn in 2023 and is predicted to grow at a CAGR of 3.9% from 2023 to 2030 to $505.5 Mn by 2030. Public health initiatives, rising incidence of infections, and a growing demand for effective treatments drive this market expansion. Leading companies in this market include GlaxoSmithKline plc (GSK), Pfizer Inc., Novartis, Takeda, and Baxter, among others.
UK Home Infusion Therapy Market
The UK Home Infusion Therapy Market was valued at $935 Mn in 2023 and is predicted to grow at a CAGR of 6.1% from 2023 to 2030, to $1415.1 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the UK Home Infusion Therapy Market are Becton, Dickinson and Company (BD), Baxter International, ICU Medical (Smiths Medical), and Fresenius Kabi, among others.
UK Hepatitis A Therapeutics Market Analysis
The UK Hepatitis A Therapeutics Market was valued at $19.17 Mn in 2023 and is predicted to grow at a CAGR of 0.2% from 2023 to 2030 to $19.44 Mn by 2030. Growing vulnerable population, a strong pharmaceutical research ecosystem, and supportive government initiatives drive the market. Key players in this sector include prominent companies like GlaxoSmithKline (GSK) and Merck & Co. Inc., which play a crucial role.
UK Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
UK Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the UK Adrenoleukodystrophy (ALD) drugs market.
UK Antibacterial (Antibiotics) Drugs Market Analysis
UK Antibacterial (Antibiotics) Drugs Market is at around $1.32 Bn in 2023 and is projected to reach $1.54 Bn in 2030, exhibiting a CAGR of 2.2% during the forecast period. The market is growing due to factors such as the aging population, rising prevalence of infectious diseases, and technological advancements. The market is dominated by key players like Wockhardt UK Ltd, Teva Pharmaceuticals Industries Ltd, AstraZeneca plc, Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.
UK Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
UK Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $59 Mn in 2022 to $102.9 Mn by 2030, registering a CAGR of 7.2% during the forecast period of 2022-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favourable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma are a few other companies that are involved in the pharmaceutical industry.